Director/PDMR Shareholding

AstraZeneca PLC
31 March 2008

Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DR 3.1.4R

We hereby inform you that on 28 March 2008, the following individuals, who are
all persons discharging managerial responsibilities, were each granted an award
under the terms of the AstraZeneca Performance Share Plan over the Company's
USD0.25 Ordinary Shares or, in the case of D Mott, L Tetrault and A Zook, over
the Company's American Depositary Shares (ADSs).  One ADS equals one Ordinary
Share

                       Target number of shares        Award price per share     Normal vesting date
Name of individual     awarded

B Angelici             37,221                         1882p                     28 March 2011

J Lundberg             36,334                         1882p                     28 March 2011

D Mott                 53,593                         US$37.76                  28 March 2011

D Smith                27,098                         1882p                     28 March 2011

L Tetrault             50,477                         US$37.76                  28 March 2011

A Zook                 72,728                         US$37.76                  28 March 2011


The AstraZeneca Performance Share Plan was approved by shareholders at the
Company's AGM in 2005.  Awards made under the Plan may not generally vest before
the third anniversary of the relevant date of grant nor unless the specified
performance target(s) have been met at the end of the three year period which,
for this award, is 1 January 2008 to 31 December 2010.

With the exception of D Mott, the performance target that applies to this award
is the Company's Total Shareholder Return ('TSR') compared to the TSR of a
selected peer group of 12 other pharmaceutical companies.  The actual number of
shares to which a participant may become unconditionally entitled will depend on
the extent to which the performance target(s) have been met.  A summary of the
Plan, including a more detailed explanation of the performance target(s), can be
found in the AstraZeneca Annual Report and Form 20-F Information 2007 which is
available on the Company's website www.astrazeneca.com.

For the award granted to D Mott, the performance condition relates to a range of
financial and other business measures in respect of the MedImmune business
measured over a three-year performance period.

G H R Musker
Company Secretary
31 March 2008




                      This information is provided by RNS
            The company news service from the London Stock Exchange